- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03018171
Intrathecal Clonidine Addiction for Combined Spinal Epidural Analgesia During Labor (ICA)
April 25, 2017 updated by: San Giovanni Calibita Fatebenefratelli Hospital
Impact on Maternal and Fetal Wellbeing and on Labor Curve of Intrathecal Clonidine Addiction for Labor Analgesia. A Randomized Controlled Trial.
The study aims to evaluate the impact of the addition of 20 mcg of intrathecal clonidine in combined spinalepidural for labor analgesia on the local anesthetic consumption, on labor performance and on maternal fetal well-being.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
268
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maria Grazia Frigo, MD
- Phone Number: +39066837258
- Email: mariagrazia.frigo@fbf-isola.it
Study Locations
-
-
-
Rome, Italy, 00186
- Recruiting
- San Giovanni Calibita Fatebenefratelli, Tiberine Island, Hospital
-
Contact:
- Marco Aversano, MD
- Phone Number: +39066837258
- Email: m.aversano@me.com
-
Principal Investigator:
- Claudia Claroni, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Written maternal informed consent
- Singleton pregnancy
- Gestational age ≥ 37 weeks,
- ASA I
- BMI < 30
- fetus in cephalic presentation
Exclusion Criteria:
- Suspect or certainty of fetal malformation,
- Presence of conditions such as preeclampsia, multiparity, preterm labor
- History of adverse reaction to α-2 adrenergic agonists
- Nicotine addiction
- Chronic use of opioid
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SC
this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
|
Intrathecal clonidine addiction
|
Active Comparator: S
this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
|
Intrathecal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
local anesthetic consumption reduction
Time Frame: 8 months
|
8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Claudia Claroni, MD, Fatebenefratelli San Giovanni Calibita - Tiberine Island
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2017
Primary Completion (Anticipated)
June 1, 2017
Study Completion (Anticipated)
August 1, 2017
Study Registration Dates
First Submitted
January 10, 2017
First Submitted That Met QC Criteria
January 10, 2017
First Posted (Estimate)
January 11, 2017
Study Record Updates
Last Update Posted (Actual)
April 27, 2017
Last Update Submitted That Met QC Criteria
April 25, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Labor Pain
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Sympatholytics
- Clonidine
- Sufentanil
Other Study ID Numbers
- 01.17
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Labor Pain
-
Cukurova UniversityRecruitingLabor Pain, Labor Perception, Hormone Levels and Childbirth ComfortTurkey
-
Soovu Labs Inc.Virginia Mason Hospital/Medical CenterNot yet recruiting
-
Bogomolets National Medical UniversityCompleted
-
Martin-Luther-Universität Halle-WittenbergRecruiting
-
Maimonides Medical CenterTerminated
-
Aretaieio HospitalRecruitingLabor Pain | Pain, Labor | EpiduralGreece
-
Mashhad University of Medical SciencesTerminatedDecrease Labor Pain
-
Amasya UniversityAtaturk UniversityNot yet recruitingSatisfaction, Patient | Pain, Labor
-
University Medical Centre LjubljanaCompletedLabor Pain | Labor; Prolonged, First Stage | Labor; Prolonged, Second StageSlovenia
Clinical Trials on Clonidine
-
BioDelivery Sciences InternationalCompletedNeuropathy | Painful Diabetic Neuropathy | Diabetic NeuropathyUnited States
-
OnxeoSimbec ResearchCompletedHealthyUnited Kingdom
-
Salem Anaesthesia Pain ClinicCompletedPain, Chronic | Insomnia ChronicCanada
-
Uwakwe Emmanuel ChijiokeRecruiting
-
Fred Hutchinson Cancer CenterInstitute for the Development of AfricaCompletedHIV Infections | HIV-1 and HSV-2 CoinfectionCameroon
-
Yung Shin Pharm. Ind. Co., Ltd.Completed
-
Afshan B. Hameed, M.D.Withdrawn
-
OnxeoCompletedOral MucositisSpain, United States, France, Germany, Hungary, Switzerland
-
The University of Texas Health Science Center,...CompletedWithdrawal; Therapeutic SubstanceUnited States
-
Addrenex Pharmaceuticals, Inc.CompletedAttention Deficit Disorder With HyperactivityUnited States